Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewRo 08-2750 is a non-peptide inhibitor of NGF that binds the NGF dimer (KD ~ 1 μM) possibly causing a conformational change. Selectively inhibits binding of NGF to p75NTR at submicromolar concentrations, and to both p75NTR and TrkA at concentrations > 5 μM. Prevents NGF-induced apoptosis in SK-N-MC cells. Suppresses cancer cell proliferation via regulation of Hippo signaling aand YAP phosphorylation.
M. Wt | 270.24 |
Formula | C13H10N4O3 |
Storage | Store at -20°C |
Purity | ≥95% (HPLC) |
CAS Number | 37854-59-4 |
PubChem ID | 17756791 |
InChI Key | JDEMVNYMYPJJIM-UHFFFAOYSA-N |
Smiles | CN1C2=CC(C=O)=C(C)C=C2N=C2C(=O)NC(=O)N=C12 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 2.7 | 10 with gentle warming |
The following data is based on the product molecular weight 270.24. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 37 mL | 185.02 mL | 370.04 mL |
0.5 mM | 7.4 mL | 37 mL | 74.01 mL |
1 mM | 3.7 mL | 18.5 mL | 37 mL |
5 mM | 0.74 mL | 3.7 mL | 7.4 mL |
References are publications that support the biological activity of the product.
Niederhauser et al (2000) NGF ligand alters NGF signaling via p75NTR and TrkA. J.Neurosci.Res. 61 263 PMID: 10900073
Arkin and Wells (2004) Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat.Rev.Drug Discov. 3 301 PMID: 15060526
Yang et al (2018) NTRK1 is a positive regulator of YAP oncogenic function. Oncogene 38 2778 PMID: 30542115
If you know of a relevant reference for Ro 08-2750, please let us know.
Keywords: Ro 08-2750, Ro 08-2750 supplier, inhibitors, inhibits, NGF, binding, p75NTR, TrkA, Neurotrophin, Receptors, p75, Trk, Receptor, Tyrosine, Kinases, RTKs, Ro08-2750, YAP, Hippo, signaling, Hippo/Yap, 2272, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Ro 08-2750. Do you know of a great paper that uses Ro 08-2750 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Ro 08-2750 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.